首页 > 最新文献

Asia Pacific Allergy最新文献

英文 中文
Preprandial food-dependent exercise-induced anaphylaxis to banana. 餐前食物依赖性运动诱发香蕉过敏性休克。
IF 1.7 Q3 ALLERGY Pub Date : 2023-12-01 Epub Date: 2023-10-09 DOI: 10.5415/apallergy.0000000000000113
Thatchai Kampitak

Food-dependent exercise-induced anaphylaxis is a disorder in which a reaction develops only in association with physical exertion that generally takes place postprandially. The reaction that occurs following food intake after exercise is uncommon. Banana is an infrequent cause of anaphylaxis, which has been previously reported in combination with postprandial exercise in only 1 patient. A probable case of preprandial food-dependent exercise-induced anaphylaxis to banana is described herein together with a brief review of recent related literature.

食物依赖性运动诱发过敏性休克是一种仅在与体力消耗有关的情况下才会发生反应的疾病,通常发生在餐后。运动后摄入食物后发生的反应并不常见。香蕉是过敏性休克的一个罕见病因,此前仅有一名患者在餐后运动时出现过香蕉过敏反应。本文描述了一例可能由餐前食物依赖性运动诱发的香蕉过敏性休克病例,并简要回顾了近期的相关文献。
{"title":"Preprandial food-dependent exercise-induced anaphylaxis to banana.","authors":"Thatchai Kampitak","doi":"10.5415/apallergy.0000000000000113","DOIUrl":"https://doi.org/10.5415/apallergy.0000000000000113","url":null,"abstract":"<p><p>Food-dependent exercise-induced anaphylaxis is a disorder in which a reaction develops only in association with physical exertion that generally takes place postprandially. The reaction that occurs following food intake after exercise is uncommon. Banana is an infrequent cause of anaphylaxis, which has been previously reported in combination with postprandial exercise in only 1 patient. A probable case of preprandial food-dependent exercise-induced anaphylaxis to banana is described herein together with a brief review of recent related literature.</p>","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":"13 4","pages":"199-200"},"PeriodicalIF":1.7,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10715744/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138795661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
APAAACI clinical pathway on direct provocation testing for penicillin allergy delabeling. APAAACI 关于青霉素过敏脱标直接激发试验的临床路径。
IF 1.7 Q3 ALLERGY Pub Date : 2023-12-01 Epub Date: 2023-10-18 DOI: 10.5415/apallergy.0000000000000122
Philip Hei Li, Bernard Yu-Hor Thong, Ruby Pawankar, Chandima Jeewandara, Rommel Crisenio M Lobo, Hye-Ryun Kang, Padukudru Anand Mahesh, Juan Meng, Sonomjamts Munkhbayarlakh, Duy Le Pham, Ticha Rerkpattanapipat, Min-Moon Tang, Masao Yamaguchi, Amir Hamzah Abdul Latiff, Iris Rengganis, Jiu-Yao Wang, Luo Zhang, Michaela Lucas

Background: Allergy to penicillin is commonly reported in many countries and is an overwhelming global public health concern. Penicillin allergy labels can lead to the use of less effective antibiotics and can be associated with antimicrobial resistance. Appropriate assessment of suspected penicillin allergy (often including skin testing, followed by drug provocation testing [DPT] performed by allergists) can prevent the unnecessary restriction of penicillin or delabelling. Many countries in the Asia Pacific (AP) have very limited access to allergy services, and there are significant disparities in the methods of evaluating penicillin allergy. Therefore, a clinical pathway for the management of penicillin allergy is essential.

Objectives: To develop a risk-stratified clinical pathway for delabeling penicillin allergy, taking into account the distinct epidemiology, patient/sensitization profiles, and disparities of allergy services or facilities within the AP.

Methods: A risk-stratified penicillin allergy delabeling clinical pathway was formulated by the Drug Allergy Committee of the Asia Pacific Association of Allergy, Asthma and Clinical Immunology. and members of the Penicillin Allergy Disparities survey in AP each representing one country/region of the AP. The clinical pathway was tested based on a database of anonymized patients who were sequentially referred for and completed penicillin allergy evaluation in Hong Kong.

Results: The clinical pathway was piloted employing a "hub-and-spoke" approach to foster multidisciplinary collaboration between allergists and nonallergists. A simulation run of the algorithm on a retrospective Hong Kong cohort of 439 patients was performed. Overall, 367 (84%) of patients were suitable for direct DPT and reduced the need for skin testing or specialist's care for 357 (97%) skin test-negative individuals. Out of the skin test-negative patients, 345 (94%) patients had a negative DPT.

Conclusions: This risk-stratification strategy for direct oral DPT can reduce the need for unnecessary skin testing in patients with low-risk penicillin allergy histories. The hub and spoke model of care may be considered for further piloting and validation in other AP populations that lack adequately trained allergists.

背景:许多国家都有青霉素过敏的报道,这是一个令人担忧的全球公共卫生问题。青霉素过敏标签可导致使用效果较差的抗生素,并可能与抗菌药耐药性有关。对疑似青霉素过敏进行适当的评估(通常包括皮试,然后由过敏学家进行药物激发试验 [DPT])可以避免不必要地限制使用青霉素或取消标签。亚太地区(AP)许多国家的过敏服务非常有限,青霉素过敏的评估方法也存在很大差异。因此,制定青霉素过敏临床治疗路径至关重要:考虑到亚太地区内不同的流行病学、患者/过敏情况以及过敏服务或设施的差异,制定一个风险分级的青霉素过敏脱敏临床路径:方法:亚太地区过敏、哮喘和临床免疫学协会药物过敏委员会和亚太地区青霉素过敏差异调查的成员各代表亚太地区的一个国家/地区,共同制定了风险分级的青霉素过敏脱敏临床路径。临床路径的测试基于一个匿名数据库,该数据库包含了在香港依次转诊并完成青霉素过敏评估的患者:临床路径采用 "中心辐射 "的方式进行试点,以促进过敏学家和非过敏学家之间的多学科合作。该算法对香港的 439 名患者进行了模拟运行。总体而言,有 367 名(84%)患者适合直接使用 DPT,并减少了 357 名(97%)皮试阴性患者的皮试或专科护理需求。在皮试阴性的患者中,有 345 人(94%)的 DPT 结果为阴性:结论:这种直接口服 DPT 的风险分级策略可减少有低风险青霉素过敏史的患者进行不必要的皮试。可以考虑在其他缺乏训练有素的过敏专科医生的 AP 群体中进一步试点和验证这种 "中心辐射 "护理模式。
{"title":"APAAACI clinical pathway on direct provocation testing for penicillin allergy delabeling.","authors":"Philip Hei Li, Bernard Yu-Hor Thong, Ruby Pawankar, Chandima Jeewandara, Rommel Crisenio M Lobo, Hye-Ryun Kang, Padukudru Anand Mahesh, Juan Meng, Sonomjamts Munkhbayarlakh, Duy Le Pham, Ticha Rerkpattanapipat, Min-Moon Tang, Masao Yamaguchi, Amir Hamzah Abdul Latiff, Iris Rengganis, Jiu-Yao Wang, Luo Zhang, Michaela Lucas","doi":"10.5415/apallergy.0000000000000122","DOIUrl":"https://doi.org/10.5415/apallergy.0000000000000122","url":null,"abstract":"<p><strong>Background: </strong>Allergy to penicillin is commonly reported in many countries and is an overwhelming global public health concern. Penicillin allergy labels can lead to the use of less effective antibiotics and can be associated with antimicrobial resistance. Appropriate assessment of suspected penicillin allergy (often including skin testing, followed by drug provocation testing [DPT] performed by allergists) can prevent the unnecessary restriction of penicillin or delabelling. Many countries in the Asia Pacific (AP) have very limited access to allergy services, and there are significant disparities in the methods of evaluating penicillin allergy. Therefore, a clinical pathway for the management of penicillin allergy is essential.</p><p><strong>Objectives: </strong>To develop a risk-stratified clinical pathway for delabeling penicillin allergy, taking into account the distinct epidemiology, patient/sensitization profiles, and disparities of allergy services or facilities within the AP.</p><p><strong>Methods: </strong>A risk-stratified penicillin allergy delabeling clinical pathway was formulated by the Drug Allergy Committee of the Asia Pacific Association of Allergy, Asthma and Clinical Immunology. and members of the Penicillin Allergy Disparities survey in AP each representing one country/region of the AP. The clinical pathway was tested based on a database of anonymized patients who were sequentially referred for and completed penicillin allergy evaluation in Hong Kong.</p><p><strong>Results: </strong>The clinical pathway was piloted employing a \"hub-and-spoke\" approach to foster multidisciplinary collaboration between allergists and nonallergists. A simulation run of the algorithm on a retrospective Hong Kong cohort of 439 patients was performed. Overall, 367 (84%) of patients were suitable for direct DPT and reduced the need for skin testing or specialist's care for 357 (97%) skin test-negative individuals. Out of the skin test-negative patients, 345 (94%) patients had a negative DPT.</p><p><strong>Conclusions: </strong>This risk-stratification strategy for direct oral DPT can reduce the need for unnecessary skin testing in patients with low-risk penicillin allergy histories. The hub and spoke model of care may be considered for further piloting and validation in other AP populations that lack adequately trained allergists.</p>","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":"13 4","pages":"142-147"},"PeriodicalIF":1.7,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10715740/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138795520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Induction of a type 2 inflammatory chronic rhinosinusitis in C57BL/6 mice. 诱导 C57BL/6 小鼠患上 2 型炎症性慢性鼻炎。
IF 1.7 Q3 ALLERGY Pub Date : 2023-12-01 Epub Date: 2023-11-02 DOI: 10.5415/apallergy.0000000000000123
Ying Li, Ping He, Bing Yan, Yimin Ren, Bangyu Cui, Ming Wang, Siyuan Ma, Jun Yang, Luo Zhang, Chengshuo Wang

Background: Eosinophilic chronic rhinosinusitis (CRS) has been widely studied for its intractability and high recurrence rate. It can be divided into pure and mixed type 2 CRS subtypes. Mouse models that reflect pure type 2 inflammation of CRS are lacking.

Objective: This study aims to establish a relatively pure type 2 CRS mouse model and compare it with 2 mixed type 2 CRS models.

Methods: Three mouse CRS models were constructed: (1) aerosol ovalbumin (OVA) + aspergillus oryzae-derived protease (AP); (2) intranasal OVA + AP; (3) Intraperitoneal then intranasal OVA + AP (n = 10 per group). Nasal, lung symptoms, IgE, inflammatory cells, cytokines, and remodeling factors were evaluated.

Results: Histological and micro-computed tomography showed inflammation, polyps, and opacification in all 3 experimental groups. The aerosol group had significantly increased local eosinophils and type 2 cytokines, while other types of cytokines showed no noticeable change. The nasal instillation groups also showed elevated other inflammatory factors and tissue polypoid changes were more pronounced. More severe pulmonary inflammation was observed with aerosol delivery.

Conclusion: Aerosol inhalation mouse model is superior for studying nasal relatively pure type 2 inflammation and lower airway comorbidities.

背景:嗜酸性粒细胞慢性鼻炎(CRS)因其难治性和高复发率而被广泛研究。它可分为纯合型和混合型 2 型 CRS 亚型。目前还缺乏反映纯合型 2 型 CRS 炎症的小鼠模型:本研究旨在建立一个相对纯合的 2 型 CRS 小鼠模型,并将其与 2 个混合型 2 型 CRS 模型进行比较:构建了三种小鼠 CRS 模型:(1) 气溶胶卵清蛋白 (OVA) + 源自曲霉菌的蛋白酶 (AP);(2) 鼻内注射 OVA + AP;(3) 先腹腔注射后鼻内注射 OVA + AP(每组 n = 10)。对鼻腔、肺部症状、IgE、炎症细胞、细胞因子和重塑因子进行了评估:结果:组织学和微型计算机断层扫描显示,所有 3 个实验组均存在炎症、息肉和不透明现象。气雾剂组的局部嗜酸性粒细胞和 2 型细胞因子明显增加,而其他类型的细胞因子则无明显变化。鼻腔灌注组也显示出其他炎症因子的升高,组织息肉样变更为明显。气溶胶给药组的肺部炎症更为严重:结论:气溶胶吸入小鼠模型更适合研究鼻腔相对纯净的 2 型炎症和下呼吸道合并症。
{"title":"Induction of a type 2 inflammatory chronic rhinosinusitis in C57BL/6 mice.","authors":"Ying Li, Ping He, Bing Yan, Yimin Ren, Bangyu Cui, Ming Wang, Siyuan Ma, Jun Yang, Luo Zhang, Chengshuo Wang","doi":"10.5415/apallergy.0000000000000123","DOIUrl":"https://doi.org/10.5415/apallergy.0000000000000123","url":null,"abstract":"<p><strong>Background: </strong>Eosinophilic chronic rhinosinusitis (CRS) has been widely studied for its intractability and high recurrence rate. It can be divided into pure and mixed type 2 CRS subtypes. Mouse models that reflect pure type 2 inflammation of CRS are lacking.</p><p><strong>Objective: </strong>This study aims to establish a relatively pure type 2 CRS mouse model and compare it with 2 mixed type 2 CRS models.</p><p><strong>Methods: </strong>Three mouse CRS models were constructed: (1) aerosol ovalbumin (OVA) + aspergillus oryzae-derived protease (AP); (2) intranasal OVA + AP; (3) Intraperitoneal then intranasal OVA + AP (n = 10 per group). Nasal, lung symptoms, IgE, inflammatory cells, cytokines, and remodeling factors were evaluated.</p><p><strong>Results: </strong>Histological and micro-computed tomography showed inflammation, polyps, and opacification in all 3 experimental groups. The aerosol group had significantly increased local eosinophils and type 2 cytokines, while other types of cytokines showed no noticeable change. The nasal instillation groups also showed elevated other inflammatory factors and tissue polypoid changes were more pronounced. More severe pulmonary inflammation was observed with aerosol delivery.</p><p><strong>Conclusion: </strong>Aerosol inhalation mouse model is superior for studying nasal relatively pure type 2 inflammation and lower airway comorbidities.</p>","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":"13 4","pages":"164-174"},"PeriodicalIF":1.7,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10715747/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138795658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immunological mechanisms of tolerance: Central, peripheral and the role of T and B cells 耐受的免疫机制:中枢、外周以及 T 细胞和 B 细胞的作用
IF 1.7 Q3 ALLERGY Pub Date : 2023-12-01 DOI: 10.5415/apallergy.0000000000000128
Xun Meng, J. Layhadi, Sean T. Keane, Natanya J.K. Cartwright, S. R. Durham, M. Shamji
T and B cells are key components of the adaptive immune system. Through their immune properties and their interactions with other immune cells and cytokines around them, they build a complex network to achieve immune tolerance and maintain homeostasis of the body. This is achieved through mechanisms of central and peripheral tolerance, both of which are associated with advantages and disadvantages. For this reason, the immune system is tightly regulated and their dysregulation can result in the subsequent initiation of various diseases. In this review, we will summarize the roles played by T cells and B cells within immune tolerance with specific examples in the context of different diseases that include allergic disease. In addition, we will also provide an overview on their suitability as biomarkers of allergen-specific immunotherapy.
T细胞和B细胞是适应性免疫系统的关键组成部分。它们通过自身的免疫特性以及与周围其他免疫细胞和细胞因子的相互作用,构建了一个复杂的网络,实现免疫耐受,维持机体的稳态。这是通过中枢和外周耐受机制实现的,两者都有优缺点。由于这个原因,免疫系统受到严格的调节,它们的失调会导致随后各种疾病的开始。在这篇综述中,我们将总结T细胞和B细胞在包括过敏性疾病在内的不同疾病的免疫耐受中所起的作用。此外,我们还将概述它们作为过敏原特异性免疫治疗生物标志物的适用性。
{"title":"Immunological mechanisms of tolerance: Central, peripheral and the role of T and B cells","authors":"Xun Meng, J. Layhadi, Sean T. Keane, Natanya J.K. Cartwright, S. R. Durham, M. Shamji","doi":"10.5415/apallergy.0000000000000128","DOIUrl":"https://doi.org/10.5415/apallergy.0000000000000128","url":null,"abstract":"T and B cells are key components of the adaptive immune system. Through their immune properties and their interactions with other immune cells and cytokines around them, they build a complex network to achieve immune tolerance and maintain homeostasis of the body. This is achieved through mechanisms of central and peripheral tolerance, both of which are associated with advantages and disadvantages. For this reason, the immune system is tightly regulated and their dysregulation can result in the subsequent initiation of various diseases. In this review, we will summarize the roles played by T cells and B cells within immune tolerance with specific examples in the context of different diseases that include allergic disease. In addition, we will also provide an overview on their suitability as biomarkers of allergen-specific immunotherapy.","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":"44 1","pages":"175 - 186"},"PeriodicalIF":1.7,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138626984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association of interleukin-13 gene single nucleotide polymorphism rs1800925 with allergic asthma in Asian population: A meta-analysis. 白细胞介素-13 基因单核苷酸多态性 rs1800925 与亚洲人群过敏性哮喘的关系:荟萃分析
IF 1.7 Q3 ALLERGY Pub Date : 2023-12-01 Epub Date: 2023-10-09 DOI: 10.5415/apallergy.0000000000000119
Kenneth V Gaceja, Zaynah Faith R Ancheta, Abigail Charisse A Buna, Sandra Mae S Clarencio, Maria Angelica R Garrido, John Donnie A Ramos

Background: The interleukin-13 (IL-13) gene has been associated with allergic asthma pathogenesis due to its role in IgE synthesis. The IL-13 single nucleotide polymorphism (SNP) rs1800925 has been implicated in exacerbated allergic asthma symptoms in different ethnicities.

Objectives: To determine the association of IL-13 SNP rs1800925 with allergic asthma symptoms in the Asian population.

Methods: Major databases were searched for studies on the association of IL-13 rs1800925 with allergic asthma in various Asian populations published between 2010 and February 2022. The odds ratio with 95% CI was obtained from included studies, and the association was evaluated using different genetic models. Heterogeneity was explored by subgroup analyses and I2 statistic evaluation.

Results: Eleven studies with a total of 2895 cases and 2914 controls were included in this meta-analysis. The majority of the cases exhibited CC genotype (n = 1897), followed by CT genotype (n = 852), and TT genotype (n = 146). IL-13 rs1800925 was significantly associated with increased allergic asthma risk in the Asian population under the recessive model (TT vs CT/CC: OR, 1.48; 95% CI, 1.14-1.93; P = 0.37; I2 = 08%). Subgroup analyses by ethnicity showed an elevated risk of allergic asthma in West Asians (Iranian and Saudi Arabian) followed by East Asians (Chinese and Japanese) using the recessive model. Both age groups (adults and children) exhibited an increased risk of allergic asthma.

Conclusion: This meta-analysis provides evidence that IL-13 SNP rs1800925 is a risk factor for allergic asthma in the Asian Population. It also suggests that rs1800925 is a risk factor present in both adult and children population.

背景:白细胞介素-13(IL-13)基因因其在 IgE 合成中的作用而与过敏性哮喘的发病机制有关。IL-13 单核苷酸多态性(SNP)rs1800925 与不同种族过敏性哮喘症状的加重有关:确定亚裔人群中 IL-13 SNP rs1800925 与过敏性哮喘症状的关联:方法:在主要数据库中检索 2010 年至 2022 年 2 月间发表的关于不同亚洲人群中 IL-13 SNP rs1800925 与过敏性哮喘相关性的研究。从纳入的研究中获得了带有 95% CI 的几率,并使用不同的遗传模型评估了相关性。通过亚组分析和 I2 统计评估探讨了异质性:本次荟萃分析共纳入了 11 项研究,共计 2895 例病例和 2914 例对照。大多数病例表现为 CC 基因型(n = 1897),其次是 CT 基因型(n = 852)和 TT 基因型(n = 146)。在隐性模型下,IL-13 rs1800925与亚洲人群过敏性哮喘风险的增加显著相关(TT vs CT/CC:OR,1.48;95% CI,1.14-1.93;P = 0.37;I2 = 08%)。按种族进行的亚组分析显示,使用隐性模型,西亚人(伊朗人和沙特阿拉伯人)患过敏性哮喘的风险较高,其次是东亚人(中国人和日本人)。两个年龄组(成人和儿童)患过敏性哮喘的风险都有所增加:这项荟萃分析提供的证据表明,IL-13 SNP rs1800925 是亚洲人群过敏性哮喘的一个风险因素。结论:这项荟萃分析提供的证据表明,IL-13 SNP rs1800925 是亚洲人群中过敏性哮喘的危险因素,同时也表明 rs1800925 在成人和儿童人群中都存在。
{"title":"Association of interleukin-13 gene single nucleotide polymorphism rs1800925 with allergic asthma in Asian population: A meta-analysis.","authors":"Kenneth V Gaceja, Zaynah Faith R Ancheta, Abigail Charisse A Buna, Sandra Mae S Clarencio, Maria Angelica R Garrido, John Donnie A Ramos","doi":"10.5415/apallergy.0000000000000119","DOIUrl":"https://doi.org/10.5415/apallergy.0000000000000119","url":null,"abstract":"<p><strong>Background: </strong>The interleukin-13 (IL-13) gene has been associated with allergic asthma pathogenesis due to its role in IgE synthesis. The IL-13 single nucleotide polymorphism (SNP) rs1800925 has been implicated in exacerbated allergic asthma symptoms in different ethnicities.</p><p><strong>Objectives: </strong>To determine the association of IL-13 SNP rs1800925 with allergic asthma symptoms in the Asian population.</p><p><strong>Methods: </strong>Major databases were searched for studies on the association of IL-13 rs1800925 with allergic asthma in various Asian populations published between 2010 and February 2022. The odds ratio with 95% CI was obtained from included studies, and the association was evaluated using different genetic models. Heterogeneity was explored by subgroup analyses and <i>I</i><sup>2</sup> statistic evaluation.</p><p><strong>Results: </strong>Eleven studies with a total of 2895 cases and 2914 controls were included in this meta-analysis. The majority of the cases exhibited CC genotype (n = 1897), followed by CT genotype (n = 852), and TT genotype (n = 146). IL-13 rs1800925 was significantly associated with increased allergic asthma risk in the Asian population under the recessive model (TT vs CT/CC: OR, 1.48; 95% CI, 1.14-1.93; <i>P</i> = 0.37; <i>I</i><sup>2</sup> = 08%). Subgroup analyses by ethnicity showed an elevated risk of allergic asthma in West Asians (Iranian and Saudi Arabian) followed by East Asians (Chinese and Japanese) using the recessive model. Both age groups (adults and children) exhibited an increased risk of allergic asthma.</p><p><strong>Conclusion: </strong>This meta-analysis provides evidence that IL-13 SNP rs1800925 is a risk factor for allergic asthma in the Asian Population. It also suggests that rs1800925 is a risk factor present in both adult and children population.</p>","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":"13 4","pages":"148-157"},"PeriodicalIF":1.7,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10715742/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138795654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The relevance of oral food challenge in a patient allergic to peanut and tree nuts. 对花生和坚果过敏的患者口服食物挑战的相关性。
IF 1.7 Q3 ALLERGY Pub Date : 2023-09-01 Epub Date: 2023-09-07 DOI: 10.5415/apallergy.0000000000000109
Rita Limão, Borja Bartolomé, Fátima Cabral Duarte

Peanut allergy is one of the most common food allergies in childhood. In vitro cross-sensitization between peanut and tree nuts (TN) is high, but only a subgroup of patients allergic to peanut will have a concomitant allergy to one or several TN. In this article, the authors report a case of a 12-year-old boy who experienced 1 episode of lips and mouth itching, generalized urticarial, and eyelid angioedema 20 minutes after ingestion of peanut at 4 years of age. The immunoallergological study revealed the presence of a concomitant allergy to peanut, pistachio, and cashew confirmed with medically supervised oral food challenges (OFC) in a child who had never eaten these TN. The mechanism of IgE-mediated hypersensitivity was demonstrated by positive skin prick tests (SPT) with commercial extracts, although the specific IgE (sIgE) for these foods was negative. As described in the literature, we concluded that serum peanut and TN sIgE measurements have lower sensitivity than SPT to assess IgE sensitization, and OFC is the gold standard for accurate diagnosis of food allergy. We highlight the relevance of excluding or confirming TN allergy in a peanut-allergic patient who had never ingested certain TN, and of knowing the clinical relevant cross-reactivity patterns between TN, pistachio/cashew, and walnut/pecan, that could reduce the need for OFC in clinical practice, reducing allergy rates and financial and health burdens of food allergy.

花生过敏是儿童时期最常见的食物过敏之一。花生和树坚果之间的体外交叉致敏(TN)很高,但只有一个对花生过敏的亚组患者会对一种或几种TN同时过敏。在本文中,作者报告了一例12岁男孩在4岁时摄入花生20分钟后出现1次唇口瘙痒、全身性荨麻疹和眼睑血管性水肿。免疫变态反应学研究显示,在一名从未食用过花生、开心果和腰果的儿童中,经医学监督的口服食物挑战(OFC)证实,存在对花生、开心果和腰腰果的伴随过敏。IgE介导的超敏反应机制通过商业提取物的阳性皮肤点刺试验(SPT)证明,尽管这些食物的特异性IgE(sIgE)为阴性。如文献所述,我们得出结论,血清花生和TN sIgE测量在评估IgE致敏性方面的敏感性低于SPT,OFC是准确诊断食物过敏的金标准。我们强调了在从未摄入某些TN的花生过敏患者中排除或确认TN过敏的相关性,以及了解TN、开心果/腰果和核桃/山核桃之间的临床相关交叉反应模式的相关性,这可以减少临床实践中对OFC的需要,降低过敏率以及食物过敏的经济和健康负担。
{"title":"The relevance of oral food challenge in a patient allergic to peanut and tree nuts.","authors":"Rita Limão,&nbsp;Borja Bartolomé,&nbsp;Fátima Cabral Duarte","doi":"10.5415/apallergy.0000000000000109","DOIUrl":"10.5415/apallergy.0000000000000109","url":null,"abstract":"<p><p>Peanut allergy is one of the most common food allergies in childhood. In vitro cross-sensitization between peanut and tree nuts (TN) is high, but only a subgroup of patients allergic to peanut will have a concomitant allergy to one or several TN. In this article, the authors report a case of a 12-year-old boy who experienced 1 episode of lips and mouth itching, generalized urticarial, and eyelid angioedema 20 minutes after ingestion of peanut at 4 years of age. The immunoallergological study revealed the presence of a concomitant allergy to peanut, pistachio, and cashew confirmed with medically supervised oral food challenges (OFC) in a child who had never eaten these TN. The mechanism of IgE-mediated hypersensitivity was demonstrated by positive skin prick tests (SPT) with commercial extracts, although the specific IgE (sIgE) for these foods was negative. As described in the literature, we concluded that serum peanut and TN sIgE measurements have lower sensitivity than SPT to assess IgE sensitization, and OFC is the gold standard for accurate diagnosis of food allergy. We highlight the relevance of excluding or confirming TN allergy in a peanut-allergic patient who had never ingested certain TN, and of knowing the clinical relevant cross-reactivity patterns between TN, pistachio/cashew, and walnut/pecan, that could reduce the need for OFC in clinical practice, reducing allergy rates and financial and health burdens of food allergy.</p>","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":"13 3","pages":"132-134"},"PeriodicalIF":1.7,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10516310/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41101327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Real-world physician practices on the diagnosis and management of allergic rhinitis in the Philippine setting. 真实世界的医生在菲律宾环境中进行过敏性鼻炎的诊断和治疗。
IF 1.7 Q3 ALLERGY Pub Date : 2023-09-01 Epub Date: 2023-09-07 DOI: 10.5415/apallergy.0000000000000112
Maria Cristina V Balotro-Torres, Frances M Tan, Cecilia Gretchen Navarro-Locsin, Marysia T Recto, Joel A Romualdez, Josephine B Ramos, Emily G Resurreccion, Rommel Crisenio M Lobo, Eloisa S de Guia, Ma Fredelita Carreon-Asuncion, Jean Bousquet

Background: Physician awareness and adherence to guidelines varies among countries and between types of physician practice. Identifying the needs of the physician and patient is essential to improve patient outcome. Data on physician diagnosis and management of allergic rhinitis (AR) in the Philippines is currently limited.

Objective: Study objectives are to assess awareness and use of guidelines, practices on diagnosis and management of intermittent and persistent AR, reasons for choice of therapy, and familiarity with immunotherapy.

Methods: A cross-section of 590 specialist and 223 subspecialist physicians from 17 regions of the Philippines were surveyed from October 2021 to July 2022. Survey consisted of a 12-point validated online questionnaire on knowledge and use of guidelines for diagnosis and treatment, use of diagnostic tests, preferred pharmacologic treatment, preferred adjuvant therapy, reasons for treatment choice, and familiarity with immunotherapy.

Results: Seventy-seven percent of respondents used Allergic Rhinitis and its Impact on Asthma guidelines for diagnosis and management of AR. Three-fifths of respondents "always" routinely evaluated AR patients' history and performed a physical examination for asthma; 57% of respondents "always" routinely evaluated asthma patients' history and performed a physical examination for AR. Allergy testing was "sometimes" recommended by 62.2%. Oral second-generation antihistamines were the preferred choice for the treatment of intermittent AR. Intranasal steroids were the preferred treatment for persistent AR. Top reasons for choice of treatment were guideline recommendations, efficacy, onset of action, cost, and availability of treatment.

Conclusion: Filipino specialists and subspecialists are aware and use guidelines in diagnosis and management of AR. Clinical history and physical examination are the cornerstone of diagnosis. Management practices for intermittent and persistent AR are similar for both groups. Recognizing the role of patient treatment preferences and allergen-specific immunotherapy remains to be a gap in the management of AR by Filipino physicians.

背景:不同国家和不同执业类型的医生对指南的认识和遵守情况各不相同。识别医生和患者的需求对于改善患者的治疗效果至关重要。菲律宾医生诊断和治疗过敏性鼻炎(AR)的数据目前有限。目的:研究目的是评估对间歇性和持续性AR的诊断和管理指南、实践、选择治疗的原因以及对免疫疗法的熟悉程度的认识和使用情况。方法:2021年10月至2022年7月,对来自菲律宾17个地区的590名专科医生和223名亚专科医生进行了横断面调查。调查包括一份12点验证的在线问卷,内容涉及诊断和治疗指南的知识和使用、诊断测试的使用、首选药物治疗、首选辅助治疗、选择治疗的原因以及对免疫疗法的熟悉程度。结果:77%的受访者使用过敏性鼻炎及其对哮喘的影响指南来诊断和管理AR。五分之三的受访者“总是”定期评估AR患者的病史并进行哮喘体检;57%的受访者“总是”定期评估哮喘患者的病史并进行AR体检。62.2%的人“有时”建议进行过敏测试。口服第二代抗组胺药是治疗间歇性AR的首选。鼻内类固醇是治疗持续性AR的首选药物。选择治疗的主要原因是指南建议、疗效、起效时间、费用和治疗的可用性。结论:菲律宾专家和专科医生了解并使用AR的诊断和管理指南。临床病史和体检是诊断的基石。间歇性AR和持续性AR的管理实践在两组中都是相似的。菲律宾医生在AR管理方面,认识到患者治疗偏好和过敏原特异性免疫疗法的作用仍然是一个空白。
{"title":"Real-world physician practices on the diagnosis and management of allergic rhinitis in the Philippine setting.","authors":"Maria Cristina V Balotro-Torres,&nbsp;Frances M Tan,&nbsp;Cecilia Gretchen Navarro-Locsin,&nbsp;Marysia T Recto,&nbsp;Joel A Romualdez,&nbsp;Josephine B Ramos,&nbsp;Emily G Resurreccion,&nbsp;Rommel Crisenio M Lobo,&nbsp;Eloisa S de Guia,&nbsp;Ma Fredelita Carreon-Asuncion,&nbsp;Jean Bousquet","doi":"10.5415/apallergy.0000000000000112","DOIUrl":"https://doi.org/10.5415/apallergy.0000000000000112","url":null,"abstract":"<p><strong>Background: </strong>Physician awareness and adherence to guidelines varies among countries and between types of physician practice. Identifying the needs of the physician and patient is essential to improve patient outcome. Data on physician diagnosis and management of allergic rhinitis (AR) in the Philippines is currently limited.</p><p><strong>Objective: </strong>Study objectives are to assess awareness and use of guidelines, practices on diagnosis and management of intermittent and persistent AR, reasons for choice of therapy, and familiarity with immunotherapy.</p><p><strong>Methods: </strong>A cross-section of 590 specialist and 223 subspecialist physicians from 17 regions of the Philippines were surveyed from October 2021 to July 2022. Survey consisted of a 12-point validated online questionnaire on knowledge and use of guidelines for diagnosis and treatment, use of diagnostic tests, preferred pharmacologic treatment, preferred adjuvant therapy, reasons for treatment choice, and familiarity with immunotherapy.</p><p><strong>Results: </strong>Seventy-seven percent of respondents used Allergic Rhinitis and its Impact on Asthma guidelines for diagnosis and management of AR. Three-fifths of respondents \"always\" routinely evaluated AR patients' history and performed a physical examination for asthma; 57% of respondents \"always\" routinely evaluated asthma patients' history and performed a physical examination for AR. Allergy testing was \"sometimes\" recommended by 62.2%. Oral second-generation antihistamines were the preferred choice for the treatment of intermittent AR. Intranasal steroids were the preferred treatment for persistent AR. Top reasons for choice of treatment were guideline recommendations, efficacy, onset of action, cost, and availability of treatment.</p><p><strong>Conclusion: </strong>Filipino specialists and subspecialists are aware and use guidelines in diagnosis and management of AR. Clinical history and physical examination are the cornerstone of diagnosis. Management practices for intermittent and persistent AR are similar for both groups. Recognizing the role of patient treatment preferences and allergen-specific immunotherapy remains to be a gap in the management of AR by Filipino physicians.</p>","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":"13 3","pages":"105-113"},"PeriodicalIF":1.7,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b3/09/pa9-13-105.PMC10516311.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41098305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A 14-year-old boy with severe erythema multiforme due to amoxicillin. 一名14岁男孩因阿莫西林引起严重多形性红斑。
IF 1.7 Q3 ALLERGY Pub Date : 2023-09-01 Epub Date: 2023-09-07 DOI: 10.5415/apallergy.0000000000000108
Mami Kurihara, Shingo Yamanishi, Saeko Ozaki, Ruby Pawankar

The most common cause of erythema multiforme (EM) in children is infectious diseases which account for approximately 90% of cases. Drug eruptions are another common cause. Here we are reporting about a male patient aged 14 years with lymphadenitis who developed severe diffuse erythema during the course of treatment with medications including several antibiotics and nonsteroidal anti-inflammatory drugs (NSAIDs). Based on the pathological findings of the skin biopsy, the skin rash was due to EM. Upon investigating the underlying cause of EM, viral antibody was positive for Coxsackie A6, lymphocyte transformation testing (LTT) was positive for one of the NSAIDs, and the patch test (PT) was positive for amoxicillin. Based on the pattern of distribution of the skin rash, the cause of EM was considered to be drug-induced eruption due to amoxicillin. In this case, we did not derive a diagnosis of drug eruption without investigating the possibility of drug induction, because most cases of EM in children are induced by infection and the antibody against Coxsackie A6 was elevated. To diagnose the possibility of amoxicillin-induced EM, it was important to distinguish between the distribution patterns of infectious versus drug-induced EM and to evaluate the possibility of drug induction by both LTT and PT. If the diagnosis of amoxicillin-induced EM, had not been made, the potential recurrence of EM with amoxicillin could have occurred.

儿童多形性红斑(EM)最常见的病因是感染性疾病,约占病例的90%。药疹是另一个常见的原因。我们报道了一名14岁的男性淋巴结炎患者,他在服用包括几种抗生素和非甾体抗炎药(NSAIDs)在内的药物治疗过程中出现了严重的弥漫性红斑。根据皮肤活检的病理结果,皮疹是由EM引起的。在调查EM的根本原因后,病毒抗体对柯萨奇A6呈阳性,淋巴细胞转化试验(LTT)对其中一种非甾体抗炎药呈阳性,贴片试验(PT)对阿莫西林呈阳性。根据皮疹的分布模式,EM的原因被认为是阿莫西林引起的药物性皮疹。在这种情况下,在没有研究药物诱导的可能性的情况下,我们没有得出药疹的诊断,因为大多数儿童EM病例是由感染诱导的,并且针对柯萨奇A6的抗体升高。为了诊断阿莫西林诱导的EM的可能性,重要的是区分感染性EM和药物诱导EM的分布模式,并评估LTT和PT诱导药物的可能性。如果没有诊断出阿莫西林诱导EM,阿莫西林可能会发生EM的潜在复发。
{"title":"A 14-year-old boy with severe erythema multiforme due to amoxicillin.","authors":"Mami Kurihara,&nbsp;Shingo Yamanishi,&nbsp;Saeko Ozaki,&nbsp;Ruby Pawankar","doi":"10.5415/apallergy.0000000000000108","DOIUrl":"https://doi.org/10.5415/apallergy.0000000000000108","url":null,"abstract":"<p><p>The most common cause of erythema multiforme (EM) in children is infectious diseases which account for approximately 90% of cases. Drug eruptions are another common cause. Here we are reporting about a male patient aged 14 years with lymphadenitis who developed severe diffuse erythema during the course of treatment with medications including several antibiotics and nonsteroidal anti-inflammatory drugs (NSAIDs). Based on the pathological findings of the skin biopsy, the skin rash was due to EM. Upon investigating the underlying cause of EM, viral antibody was positive for Coxsackie A6, lymphocyte transformation testing (LTT) was positive for one of the NSAIDs, and the patch test (PT) was positive for amoxicillin. Based on the pattern of distribution of the skin rash, the cause of EM was considered to be drug-induced eruption due to amoxicillin. In this case, we did not derive a diagnosis of drug eruption without investigating the possibility of drug induction, because most cases of EM in children are induced by infection and the antibody against Coxsackie A6 was elevated. To diagnose the possibility of amoxicillin-induced EM, it was important to distinguish between the distribution patterns of infectious versus drug-induced EM and to evaluate the possibility of drug induction by both LTT and PT. If the diagnosis of amoxicillin-induced EM, had not been made, the potential recurrence of EM with amoxicillin could have occurred.</p>","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":"13 3","pages":"135-138"},"PeriodicalIF":1.7,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/45/cf/pa9-13-135.PMC10516312.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41099780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluating immune responses to pneumococcal vaccines. 评估肺炎球菌疫苗的免疫反应。
IF 1.7 Q3 ALLERGY Pub Date : 2023-09-01 Epub Date: 2023-09-07 DOI: 10.5415/apallergy.0000000000000114
Bernard Yu-Hor Thong, Ruby Pawankar, Hae-Sim Park, Amir Hamzah Abdul Latiff

Streptococcus pneumoniae (pneumococcus) is a significant cause of bacterial infections ranging from mild infections affecting the respiratory tract such as otitis media and sinusitis to severe diseases including bacteremia, pneumonia, and invasive pneumococcal disease (IPD) (eg, meningitis, septic arthritis, and endocarditis). Pneumococcal vaccines were first developed in the 1970s as capsular pneumococcal polysaccharide vaccines, which were T-cell independent and hence lacked immunologic memory. Subsequently in the year 2000, pneumococcal conjugate vaccines (PCV) conjugated to a protein to increase immunogenicity were developed and made commercially available. The increasing number of pneumococcal serotypes identified and the expanding pipeline of PCV vaccines with improved immunogenicity have significantly reduced the morbidity and mortality associated with IPD in high-risk patients. Pneumococcal vaccines also play an important role in the diagnosis and immunophenotyping of children and adults with inborn errors of immunity (IEI) given the increasing diversity/heterogeneity of IEI presenting with primary and/or specific antibody deficiency. Other than the quantitation of serotype levels in routine clinical care, other measurements of immune response including the functional activity of antibodies, antibody avidity, cell-mediated immunity, and immunological memory remain limited to clinical trials during vaccine development.

肺炎链球菌(肺炎球菌)是细菌感染的重要原因,从影响呼吸道的轻度感染(如中耳炎和鼻窦炎)到严重疾病(包括菌血症、肺炎和侵袭性肺炎球菌疾病(IPD)(如脑膜炎、感染性关节炎和心内膜炎)。肺炎球菌疫苗最早是在20世纪70年代作为荚膜肺炎球菌多糖疫苗开发的,它是不依赖于T细胞的,因此缺乏免疫记忆。随后在2000年,开发了与蛋白质结合以提高免疫原性的肺炎球菌结合疫苗(PCV),并将其商业化。已鉴定的肺炎球菌血清型数量的增加以及免疫原性提高的PCV疫苗的不断扩大,显著降低了高危患者与IPD相关的发病率和死亡率。肺炎球菌疫苗在先天性免疫缺陷(IEI)儿童和成人的诊断和免疫表型中也发挥着重要作用,因为IEI的多样性/异质性日益增加,表现为原发性和/或特异性抗体缺乏。除了常规临床护理中血清型水平的定量外,免疫反应的其他测量,包括抗体的功能活性、抗体亲和力、细胞介导的免疫和免疫记忆,仍仅限于疫苗开发期间的临床试验。
{"title":"Evaluating immune responses to pneumococcal vaccines.","authors":"Bernard Yu-Hor Thong,&nbsp;Ruby Pawankar,&nbsp;Hae-Sim Park,&nbsp;Amir Hamzah Abdul Latiff","doi":"10.5415/apallergy.0000000000000114","DOIUrl":"https://doi.org/10.5415/apallergy.0000000000000114","url":null,"abstract":"<p><p><i>Streptococcus pneumoniae</i> (pneumococcus) is a significant cause of bacterial infections ranging from mild infections affecting the respiratory tract such as otitis media and sinusitis to severe diseases including bacteremia, pneumonia, and invasive pneumococcal disease (IPD) (eg, meningitis, septic arthritis, and endocarditis). Pneumococcal vaccines were first developed in the 1970s as capsular pneumococcal polysaccharide vaccines, which were T-cell independent and hence lacked immunologic memory. Subsequently in the year 2000, pneumococcal conjugate vaccines (PCV) conjugated to a protein to increase immunogenicity were developed and made commercially available. The increasing number of pneumococcal serotypes identified and the expanding pipeline of PCV vaccines with improved immunogenicity have significantly reduced the morbidity and mortality associated with IPD in high-risk patients. Pneumococcal vaccines also play an important role in the diagnosis and immunophenotyping of children and adults with inborn errors of immunity (IEI) given the increasing diversity/heterogeneity of IEI presenting with primary and/or specific antibody deficiency. Other than the quantitation of serotype levels in routine clinical care, other measurements of immune response including the functional activity of antibodies, antibody avidity, cell-mediated immunity, and immunological memory remain limited to clinical trials during vaccine development.</p>","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":"13 3","pages":"127-131"},"PeriodicalIF":1.7,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10516308/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41103858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pandemic effects on the care of patients with inborn errors of immunity. 流行病对先天性免疫缺陷患者护理的影响。
IF 1.7 Q3 ALLERGY Pub Date : 2023-09-01 Epub Date: 2023-09-11 DOI: 10.5415/apallergy.0000000000000117
Amir Hamzah Abdul Latiff
It is evident that the COVID-19 pandemic has challenged the healthcare systems worldwide and exposed many deficiencies in these systems and required restructuring to mitigate these deficiencies in a modern-day pandemic [1]. A myriad of effects resulting from this pandemic not only have an impact physiologically, but also psychologically and thus, has had a huge impact on the mental health of the global community [2]. Enormous resources were required to provide continuous high-level care for those infected and this led to the neglect of uninfected patients with chronic diseases. These chronic diseases include inborn errors of immunity (IEI) for which nearly 500 gene defects have been described [3]. IEI present typically with recurring infections, but also as autoimmune, autoinflammatory, and allergic conditions. Even in the nonpandemic circumstances, patients with IEI and their caregivers would report significant care inadequacies, both in diagnostic and therapeutic care. In general, IEI are usually underdiagnosed and this could have worsened during the pandemic leading to further morbidity and mortality. On the other hand, several groups have also assessed the possibility of novel IEI presenting as severe COVID-19 infection and has led to the discovery of new IEI gene defects [4, 5]. This highlights and strengthens the observation that IEI as an experiment of nature, aids in progressive understanding of the human immune system, and thereby provides opportunities in developing targeted therapies for immune-mediated diseases. It also illustrates the importance of the field of clinical immunology during any pandemic and that immunologists, both clinical and scientists alike, play a central role in managing any pandemic. The need for a lockdown to mitigate the spread of the recent COVID-19 pandemic had detrimental effects on an effective delivery of treatment to IEI patients. Depending on the type of IEI, therapeutic options include antibiotics prophylaxis, immunoglobulin replacement therapy (IRT), hemopoietic stem cell transplant, and gene therapy. The mainstay of treatments for most patients with IEI, that is, predominantly antibody deficiencies is IRT, which is commonly delivered intravenously, and possibly subcutaneously. Immunoglobulin therapy contains antibodies to compensate for the defective immune system’s inability to produce them. Individuals with IEI need IRT regularly throughout their lives to help combat infections and prevent organ damage. Without IRT, they are in danger of suffering from morbidity, poor quality of life, and reduced life expectancy. As immunoglobulin is derived from human plasma, there are concerns about the availability of supply, particularly to treat life-threatening conditions that cannot be improved with other medications. It is estimated that 75% to 80% of IEI patients do not have access to adequate immunoglobulin therapy throughout the world [6]. Certainly, delivery of IRT was affected during the pandemic due to
{"title":"Pandemic effects on the care of patients with inborn errors of immunity.","authors":"Amir Hamzah Abdul Latiff","doi":"10.5415/apallergy.0000000000000117","DOIUrl":"https://doi.org/10.5415/apallergy.0000000000000117","url":null,"abstract":"It is evident that the COVID-19 pandemic has challenged the healthcare systems worldwide and exposed many deficiencies in these systems and required restructuring to mitigate these deficiencies in a modern-day pandemic [1]. A myriad of effects resulting from this pandemic not only have an impact physiologically, but also psychologically and thus, has had a huge impact on the mental health of the global community [2]. Enormous resources were required to provide continuous high-level care for those infected and this led to the neglect of uninfected patients with chronic diseases. These chronic diseases include inborn errors of immunity (IEI) for which nearly 500 gene defects have been described [3]. IEI present typically with recurring infections, but also as autoimmune, autoinflammatory, and allergic conditions. Even in the nonpandemic circumstances, patients with IEI and their caregivers would report significant care inadequacies, both in diagnostic and therapeutic care. In general, IEI are usually underdiagnosed and this could have worsened during the pandemic leading to further morbidity and mortality. On the other hand, several groups have also assessed the possibility of novel IEI presenting as severe COVID-19 infection and has led to the discovery of new IEI gene defects [4, 5]. This highlights and strengthens the observation that IEI as an experiment of nature, aids in progressive understanding of the human immune system, and thereby provides opportunities in developing targeted therapies for immune-mediated diseases. It also illustrates the importance of the field of clinical immunology during any pandemic and that immunologists, both clinical and scientists alike, play a central role in managing any pandemic. The need for a lockdown to mitigate the spread of the recent COVID-19 pandemic had detrimental effects on an effective delivery of treatment to IEI patients. Depending on the type of IEI, therapeutic options include antibiotics prophylaxis, immunoglobulin replacement therapy (IRT), hemopoietic stem cell transplant, and gene therapy. The mainstay of treatments for most patients with IEI, that is, predominantly antibody deficiencies is IRT, which is commonly delivered intravenously, and possibly subcutaneously. Immunoglobulin therapy contains antibodies to compensate for the defective immune system’s inability to produce them. Individuals with IEI need IRT regularly throughout their lives to help combat infections and prevent organ damage. Without IRT, they are in danger of suffering from morbidity, poor quality of life, and reduced life expectancy. As immunoglobulin is derived from human plasma, there are concerns about the availability of supply, particularly to treat life-threatening conditions that cannot be improved with other medications. It is estimated that 75% to 80% of IEI patients do not have access to adequate immunoglobulin therapy throughout the world [6]. Certainly, delivery of IRT was affected during the pandemic due to","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":"13 3","pages":"95-96"},"PeriodicalIF":1.7,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/39/10/pa9-13-095.PMC10516314.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41095433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Asia Pacific Allergy
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1